The use of laboratory methods in differential diagnosis and treatment of SLE and antiphospholipid syndrome

References

• Swaak AJ, Huysen V, Nossent JC, Smeenk RJ. Antinuclear antibody profiles in relation to specific disease manifestations of systemic lupus erythematosus. Clin. Rheumatol.9(1), 82–94 (1990).
   PubMedGoogle Scholar
• Canoso RT, de Oliveira RM. Characterization and antigenic specificity of chlorpromazine-induced antinuclear antibodies. J. Lab. Clin. Med.108(3), 213–216 (1986).
   PubMedGoogle Scholar
• Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin. Arthritis Rheum.34(2), 501–537 (2004).
   PubMed Web of Science ®Google Scholar
• Lefkowith JB, Gilkeson GS. Nephritogenic autoantibodies in lupus: current concepts and continuing controversies. Arthritis Rheum.39(6), 894–903 (1996).
   PubMed Web of Science ®Google Scholar
• Sthoeger ZM, Tartakovsky B, Bentwich Z, Mozes E. Monoclonal anticardiolipin antibodies derived from mice with experimental lupus erythematosus: characterization and the induction of a secondary antiphospholipid syndrome. J. Clin. Immunol.13(2), 127–138 (1993).
   PubMedGoogle Scholar
• Sheldon J. Laboratory testing in autoimmune rheumatic diseases. Best Pract. Res. Clin. Rheumatol.18(3), 249–269 (2004).
   PubMed Web of Science ®Google Scholar
• Hargreaves MM, Richmond H, Morton R. Presentation of two bone marrow elements: the “Tart” cell and the “LE” cell. Mayo. Clin. Proc.23, 25–218 (1948).
   Google Scholar
• Holborow J, Weir DM. A serum factor in lupus erythematosus with affinity for tissue nuclei. Br. Med. J.2, 732–734 (1957).
   PubMed Web of Science ®Google Scholar
• Holman HR, Kunkel HG. Affinity between the lupus erythematosus serum factor and cell nuclei and nucleoprotein. Science126, 162–163 (1957).
   PubMed Web of Science ®Google Scholar
• Toolan HW. Transplantable human neoplasms maintained in cortisone-treated laboratory animals: H.S. No. 1; H.Ep. No. 1; H.Ep. No. 2; H.Ep. No. 3; and H.Emb.Rh. No. 1. Cancer Res.14(9), 660–666 (1954).
   PubMedGoogle Scholar
• Moore AE, Sabachewsky L, Toolan HW. Culture characteristics of four permanent lines of human cancer cells. Cancer Res.15(9), 598–602 (1955).
   PubMed Web of Science ®Google Scholar
• Solomon DH, Kavanaugh AJ, Schur PH. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum.47(4), 434–444 (2002).
   PubMed Web of Science ®Google Scholar
• Emlen W, O’Neill L. Clinical significance of antinuclear antibodies: comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays. Arthritis Rheum.40(9), 1612–1618 (1997).
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y, Isenberg DA. The mosaic of autoimmunity. Immunol. Today10(4), 123–126 (1989).
   PubMedGoogle Scholar
• Rubin RL, Bell SA, Burlingame RW. Autoantibodies associated with lupus induced by diverse drugs target a similar epitope in the (H2A-H2B)–DNA complex. J. Clin. Invest.90(1), 165–173 (1992).
   PubMed Web of Science ®Google Scholar
• Eriksson C, Engstrand S, Sundqvist KG, Rantapaa-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF α. Ann. Rheum. Dis.64(3), 403–407 (2005).
   PubMed Web of Science ®Google Scholar
• Arbuckle MR, McClain MT, Rubertone MV et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med.349(16), 1526–1533 (2003).
   PubMed Web of Science ®Google Scholar
• Worrall JG, Snaith ML, Batchelor JR, Isenberg DA. SLE: a rheumatological view. Analysis of the clinical features, serology and immunogenetics of 100 SLE patients during long-term follow-up. Q. J. Med.74(275), 319–330 (1990).
   PubMedGoogle Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum.40(9), 1725 (1997).
   PubMed Web of Science ®Google Scholar
• Waldman M, Madaio MP. Pathogenic autoantibodies in lupus nephritis. Lupus14(1), 19–24 (2005).
   PubMed Web of Science ®Google Scholar
• Mannik M, Merrill CE, Stamps LD, Wener MH. Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus. J. Rheumatol.30(7), 1495–1504 (2003).
   PubMed Web of Science ®Google Scholar
• Deshmukh US, Bagavant H, Fu SM. Role of anti-DNA antibodies in the pathogenesis of lupus nephritis. Autoimmun. Rev.5(6), 414–418 (2006).
   PubMed Web of Science ®Google Scholar
• Kavanaugh AF, Solomon DH. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests. Arthritis Rheum.47(5), 546–555 (2002).
   PubMed Web of Science ®Google Scholar
• Tan EM, Smolen JS, McDougal JS et al. A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. II. Potential for quantitation of antibody content. J. Rheumatol.29(1), 68–74 (2002).
   PubMedGoogle Scholar
• Fritzler MJ, Wiik A, Tan EM et al. A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. III. Comparative performance characteristics of academic and manufacturers’ laboratories. J. Rheumatol.30(11), 2374–2381 (2003).
   PubMed Web of Science ®Google Scholar
• Smeenk RJ, van den Brink HG, Brinkman K, Termaat RM, Berden JH, Swaak AJ. Anti-dsDNA: choice of assay in relation to clinical value. Rheumatol. Int.11(3), 101–107 (1991).
   PubMed Web of Science ®Google Scholar
• Riboldi P, Gerosa M, Moroni G et al. Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus? Autoimmunity38(1), 39–45 (2005).
   PubMed Web of Science ®Google Scholar
• Wallace DA, Hahn BH. Dubois’ Lupus Erythematosus. Lippincott Williams & Wilkins, PA, USA (2007).
   Google Scholar
• Neogi T, Gladman DD, Ibanez D, Urowitz M. Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent. J. Rheumatol.33(9), 1785–1788 (2006).
   PubMed Web of Science ®Google Scholar
• ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum.33(5), 634–643 (1990).
   PubMed Web of Science ®Google Scholar
• Bootsma H, Spronk P, Derksen R et al. Prevention of relapses in systemic lupus erythematosus. Lancet345(8965), 1595–1599 (1995).
   PubMedGoogle Scholar
• Linnik MD, Hu JZ, Heilbrunn KR, Strand V, Hurley FL, Joh T. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum.52(4), 1129–1137 (2005).
   PubMed Web of Science ®Google Scholar
• Esdaile JM, Abrahamowicz M, Joseph L, MacKenzie T, Li Y, Danoff D. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. Arthritis Rheum.39(3), 370–378 (1996).
   PubMed Web of Science ®Google Scholar
• Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum.34(8), 937–944 (1991).
   PubMed Web of Science ®Google Scholar
• Ho A, Magder LS, Barr SG, Petri M. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum.44(10), 2342–2349 (2001).
   PubMed Web of Science ®Google Scholar
• Tseng CE, Buyon JP, Kim M et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum.54(11), 3623–3632 (2006).
   PubMed Web of Science ®Google Scholar
• Yee CS, Hussein H, Skan J, Bowman S, Situnayake D, Gordon C. Association of damage with autoantibody profile, age, race, sex and disease duration in systemic lupus erythematosus. Rheumatology (Oxford)42(2), 276–279 (2003).
   PubMed Web of Science ®Google Scholar
• Prasad R, Ibanez D, Gladman D, Urowitz M. Anti-dsDNA and anti-Sm antibodies do not predict damage in systemic lupus erythematosus. Lupus15(5), 285–291 (2006).
   PubMed Web of Science ®Google Scholar
• Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum.43(8), 1801–1808 (2000).
   PubMed Web of Science ®Google Scholar
• Schmauss C, McAllister G, Ohosone Y, Hardin JA, Lerner MR. A comparison of snRNP-associated Sm-autoantigens: human N, rat N and human B/B’. Nucleic Acids Res.17(4), 1733–1743 (1989).
   PubMedGoogle Scholar
• Rokeach LA, Haselby JA, Hoch SO. Molecular cloning of a cDNA encoding the human Sm-D autoantigen. Proc. Natl Acad. Sci. USA85(13), 4832–4836 (1988).
   PubMed Web of Science ®Google Scholar
• Hinterberger M, Pettersson I, Steitz JA. Isolation of small nuclear ribonucleoproteins containing U1, U2, U4, U5, and U6 RNAs. J. Biol. Chem.258(4), 2604–2613 (1983).
   PubMed Web of Science ®Google Scholar
• Harley JB, Gaither KK. Autoantibodies. Rheum. Dis. Clin. North Am.14(1), 43–56 (1988).
   PubMedGoogle Scholar
• Benito-Garcia E, Schur PH, Lahita R. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-Sm and anti-RNP antibody tests. Arthritis Rheum.51(6), 1030–1044 (2004).
   PubMedGoogle Scholar
• McCarty GA, Harley JB, Reichlin M. A distinctive autoantibody profile in black female patients with lupus nephritis. Arthritis Rheum.36(11), 1560–1565 (1993).
   PubMedGoogle Scholar
• Thompson D, Juby A, Davis P. The clinical significance of autoantibody profiles in patients with systemic lupus erythematosus. Lupus2(1), 15–19 (1993).
   PubMed Web of Science ®Google Scholar
• Munves EF, Schur PH. Antibodies to Sm and RNP. Prognosticators of disease involvement. Arthritis Rheum.26(7), 848–853 (1983).
   PubMedGoogle Scholar
• Alba P, Bento L, Cuadrado MJ et al. Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann. Rheum. Dis.62(6), 556–560 (2003).
   PubMed Web of Science ®Google Scholar
• Reveille JD. Predictive value of autoantibodies for activity of systemic lupus erythematosus. Lupus13(5), 290–297 (2004).
   PubMed Web of Science ®Google Scholar
• Migliorini P, Baldini C, Rocchi V, Bombardieri S. Anti-Sm and anti-RNP antibodies. Autoimmunity38(1), 47–54 (2005).
   PubMed Web of Science ®Google Scholar
• Egner W. The use of laboratory tests in the diagnosis of SLE. J. Clin. Pathol.53(6), 424–432 (2000).
   PubMed Web of Science ®Google Scholar
• Kurien BT, Scofield RH. Autoantibody determination in the diagnosis of systemic lupus erythematosus. Scand. J. Immunol.64(3), 227–235 (2006).
   PubMed Web of Science ®Google Scholar
• Franceschini F, Cavazzana I. Anti-Ro/SSA and La/SSB antibodies. Autoimmunity38(1), 55–63 (2005).
   PubMed Web of Science ®Google Scholar
• James JA, Dickey WD, Fujisaku A et al. Antigenicity of a recombinant Ro (SS-A) fusion protein. Arthritis Rheum.33(1), 102–106 (1990).
   PubMedGoogle Scholar
• Hedgpeth MT, Boulware DW. Interstitial pneumonitis in antinuclear antibody-negative systemic lupus erythematosus: a new clinical manifestation and possible association with anti-Ro (SS-A) antibodies. Arthritis Rheum.31(4), 545–548 (1988).
   PubMedGoogle Scholar
• Adachi M, Mita S, Obana M, Matsuoka Y, Harada K, Irimajiri S. Thrombocytopenia subsequently develops systemic lupus erythematosus – can anti-SS-A antibody predict the next event? Jpn J. Med.29(5), 481–486 (1990).
   PubMedGoogle Scholar
• Bell DA, Smeenk RJ. Clinical connections: assays and assignment. Lupus6(3), 305–306 (1997).
   PubMedGoogle Scholar
• Harley JB, Sestak AL, Willis LG, Fu SM, Hansen JA, Reichlin M. A model for disease heterogeneity in systemic lupus erythematosus. Relationships between histocompatibility antigens, autoantibodies, and lymphopenia or renal disease. Arthritis Rheum.32(7), 826–836 (1989).
   PubMed Web of Science ®Google Scholar
• Wasicek CA, Reichlin M. Clinical and serological differences between systemic lupus erythematosus patients with antibodies to Ro versus patients with antibodies to Ro and La. J. Clin. Invest.69(4), 835–843 (1982).
   PubMedGoogle Scholar
• Gomez-Puerta JA, Burlingame RW, Cervera R. Anti-chromatin (anti-nucleosome) antibodies. Lupus15(7), 408–411 (2006).
   PubMed Web of Science ®Google Scholar
• Burlingame RW. The clinical utility of antihistone antibodies. Autoantibodies reactive with chromatin in systemic lupus erythematosus and drug-induced lupus. Clin. Lab. Med.17(3), 367–378 (1997).
   PubMed Web of Science ®Google Scholar
• Chabre H, Amoura Z, Piette JC, Godeau P, Bach JF, Koutouzov S. Presence of nucleosome-restricted antibodies in patients with systemic lupus erythematosus. Arthritis Rheum.38(10), 1485–1491 (1995).
   PubMedGoogle Scholar
• Cervera R, Vinas O, Ramos-Casals M et al. Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. Ann. Rheum. Dis.62(5), 431–434 (2003).
   PubMed Web of Science ®Google Scholar
• Ghirardello A, Doria A, Zampieri S et al. Antinucleosome antibodies in SLE: a two-year follow-up study of 101 patients. J. Autoimmun.22(3), 235–240 (2004).
   PubMedGoogle Scholar
• Gomez-Puerta JA, Molina JF, Amaya JM, Molina J. Clinical significance of anti-chromatin antibodies in systemic lupus erythematosus. Lupus10(Suppl. 1), S73 (2001).
   Google Scholar
• Schett G, Smole J, Zimmermann C et al. The autoimmune response to chromatin antigens in systemic lupus erythematosus: autoantibodies against histone H1 are a highly specific marker for SLE associated with increased disease activity. Lupus11(11), 704–715 (2002).
   PubMed Web of Science ®Google Scholar
• Simon JA, Cabiedes J, Ortiz E, Alcocer-Varela J, Sanchez-Guerrero J. Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker. Rheumatology (Oxf.)43(2), 220–224 (2004).
   PubMedGoogle Scholar
• Ng KP, Manson JJ, Rahman A, Isenberg DA. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum.55(6), 900–904 (2006).
   PubMed Web of Science ®Google Scholar
• Min DJ, Kim SJ, Park SH et al. Anti-nucleosome antibody: significance in lupus patients lacking anti-double-stranded DNA antibody. Clin. Exp. Rheumatol.20(1), 13–18 (2002).
   PubMed Web of Science ®Google Scholar
• Su Y, Jia RL, Han L, Li ZG. Role of anti-nucleosome antibody in the diagnosis of systemic lupus erythematosus. Clin. Immunol.122(1), 115–120 (2007).
   PubMedGoogle Scholar
• Elkon K, Skelly S, Parnassa A et al. Identification and chemical synthesis of a ribosomal protein antigenic determinant in systemic lupus erythematosus. Proc. Natl Acad. Sci. USA83(19), 7419–7423 (1986).
   PubMed Web of Science ®Google Scholar
• Teh LS, Lee MK, Wang F et al. Antiribosomal P protein antibodies in different populations of patients with systemic lupus erythematosus. Br. J. Rheumatol.32(8), 663–665 (1993).
   PubMedGoogle Scholar
• Teh LS, Isenberg DA. Antiribosomal P protein antibodies in systemic lupus erythematosus. A reappraisal. Arthritis Rheum.37(3), 307–315 (1994).
   PubMedGoogle Scholar
• Arnett FC, Reveille JD, Moutsopoulos HM, Georgescu L, Elkon KB. Ribosomal P autoantibodies in systemic lupus erythematosus. Frequencies in different ethnic groups and clinical and immunogenetic associations. Arthritis Rheum.39(11), 1833–1839 (1996).
   PubMed Web of Science ®Google Scholar
• Eber T, Chapman J, Shoenfeld Y. Anti-ribosomal P-protein and its role in psychiatric manifestations of systemic lupus erythematosus: myth or reality? Lupus14(8), 571–575 (2005).
   PubMed Web of Science ®Google Scholar
• Bonfa E, Golombek SJ, Kaufman LD et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N. Engl. J. Med.317(5), 265–271 (1987).
   PubMed Web of Science ®Google Scholar
• Schneebaum AB, Singleton JD, West SG et al. Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am. J. Med.90(1), 54–62 (1991).
   PubMed Web of Science ®Google Scholar
• Karassa FB, Afeltra A, Ambrozic A et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum.54(1), 312–324 (2006).
   PubMed Web of Science ®Google Scholar
• do Nascimento AP, Viana Vdos S, Testagrossa Lde A et al. Antibodies to ribosomal P proteins: a potential serologic marker for lupus membranous glomerulonephritis. Arthritis Rheum.54(5), 1568–1572 (2006).
   PubMedGoogle Scholar
• Bertolaccini ML, Murru V, Alba P, Khamashta MA. Lack of association of antibodies to ribosomal P proteins with lupus membranous glomerulonephritis: comment on the article by Do Nascimento et al.Arthritis Rheum.54(12), 4025–4026 (2006).
   PubMedGoogle Scholar
• Walport MJ. Complement. First of two parts. N. Engl. J. Med.344(14), 1058–1066 (2001).
   PubMed Web of Science ®Google Scholar
• Walport MJ. Complement. Second of two parts. N. Engl. J. Med.344(15), 1140–1144 (2001).
   PubMed Web of Science ®Google Scholar
• Bowness P, Davies KA, Norsworthy PJ et al. Hereditary C1q deficiency and systemic lupus erythematosus. Q. J. Med.87(8), 455–464 (1994).
   Google Scholar
• Gunnarsson I, Ronnelid J, Huang YH et al. Association between ongoing anti-C1q antibody production in peripheral blood and proliferative nephritis in patients with active systemic lupus erythematosus. Br. J. Rheumatol.36(1), 32–37 (1997).
   PubMedGoogle Scholar
• Horvath L, Czirjak L, Fekete B et al. High levels of antibodies against Clq are associated with disease activity and nephritis but not with other organ manifestations in SLE patients. Clin. Exp. Rheumatol.19(6), 667–672 (2001).
   PubMed Web of Science ®Google Scholar
• Seelen MA, Trouw LA, Daha MR. Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus. Curr. Opin. Nephrol. Hypertens.12(6), 619–624 (2003).
   PubMed Web of Science ®Google Scholar
• Trouw LA, Daha MR. Role of anti-C1q autoantibodies in the pathogenesis of lupus nephritis. Expert Opin. Biol. Ther.5(2), 243–251 (2005).
   PubMed Web of Science ®Google Scholar
• Flierman R, Daha MR. Pathogenic role of anti-C1q autoantibodies in the development of lupus nephritis – a hypothesis. Mol. Immunol.44(1–3), 133–138 (2007).
   PubMed Web of Science ®Google Scholar
• Fremeaux-Bacchi V, Noel LH, Schifferli JA. No lupus nephritis in the absence of antiC1q autoantibodies? Nephrol. Dial. Transplant.17(12), 2041–2043 (2002).
   PubMedGoogle Scholar
• Marto N, Bertolaccini ML, Calabuig E, Hughes GR, Khamashta MA. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann. Rheum. Dis.64(3), 444–448 (2005).
   PubMed Web of Science ®Google Scholar
• Hughes GR. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br. Med. J. (Clin. Res. Ed.)287(6399), 1088–1089 (1983).
   PubMed Web of Science ®Google Scholar
• Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum.42(7), 1309–1311 (1999).
   PubMed Web of Science ®Google Scholar
• Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb. Haemost.74(4), 1185–1190 (1995).
   PubMed Web of Science ®Google Scholar
• Cervera R, Piette JC, Font J et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum.46(4), 1019–1027 (2002).
   PubMed Web of Science ®Google Scholar
• Harris EN, Gharavi AE, Wasley GD, Hughes GR. Use of an enzyme-linked immunosorbent assay and of inhibition studies to distinguish between antibodies to cardiolipin from patients with syphilis or autoimmune disorders. J. Infect. Dis.157(1), 23–31 (1988).
   PubMed Web of Science ®Google Scholar
• Galvez J, Martin I, Merino D, Pujol E. Thrombophlebitis in a patient with acute Q fever and anticardiolipin antibodies. Med. Clin. (Barc.)108(10), 396–397 (1997).
   PubMedGoogle Scholar
• Intrator L, Oksenhendler E, Desforges L, Bierling P. Anticardiolipin antibodies in HIV infected patients with or without immune thrombocytopenic purpura. Br. J. Haematol.68(2), 269–270 (1988).
   PubMedGoogle Scholar
• Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann. Intern. Med.112(9), 682–698 (1990).
   PubMed Web of Science ®Google Scholar
• Ginsburg KS, Liang MH, Newcomer L et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann. Intern. Med.117(12), 997–1002 (1992).
   PubMed Web of Science ®Google Scholar
• Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am. J. Med.104(4), 332–338 (1998).
   PubMed Web of Science ®Google Scholar
• Finazzi G, Brancaccio V, Moia M et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am. J. Med.100(5), 530–536 (1996).
   PubMed Web of Science ®Google Scholar
• Escalante A, Brey RL, Mitchell BD Jr, Dreiner U. Accuracy of anticardiolipin antibodies in identifying a history of thrombosis among patients with systemic lupus erythematosus. Am. J. Med.98(6), 559–565 (1995).
   PubMed Web of Science ®Google Scholar
• Levine SR, Salowich-Palm L, Sawaya KL et al. IgG anticardiolipin antibody titer >40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke28(9), 1660–1665 (1997).
   PubMed Web of Science ®Google Scholar
• Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus – a meta-analysis. Lupus6(5), 467–473 (1997).
   PubMed Web of Science ®Google Scholar
• Wahl DG, Guillemin F, de Maistre E, Perret-Guillaume C, Lecompte T, Thibaut G. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus7(1), 15–22 (1998).
   PubMed Web of Science ®Google Scholar
• Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J. Exp. Med.179(2), 457–462 (1994).
   PubMed Web of Science ®Google Scholar
• Roubey RA, Eisenberg RA, Harper MF, Winfield JB. “Anticardiolipin” autoantibodies recognize β2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J. Immunol.154(2), 954–960 (1995).
   PubMed Web of Science ®Google Scholar
• Amengual O, Atsumi T, Khamashta MA, Koike T, Hughes GR. Specificity of ELISA for antibody to β2-glycoprotein I in patients with antiphospholipid syndrome. Br. J. Rheumatol.35(12), 1239–1243 (1996).
   PubMedGoogle Scholar
• Cabral AR, Amigo MC, Cabiedes J, Alarcon-Segovia D. The antiphospholipid/cofactor syndromes: a primary variant with antibodies to β2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays. Am. J. Med.101(5), 472–481 (1996).
   PubMed Web of Science ®Google Scholar
• Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost.4(2), 295–306 (2006).
   PubMed Web of Science ®Google Scholar
• Galli M, Luciani D, Bertolini G, Barbui T. Anti-β2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood102(8), 2717–2723 (2003).
   PubMed Web of Science ®Google Scholar
• Bertolaccini ML, Atsumi T, Koike T, Hughes GR, Khamashta MA. Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb. Haemost.9(2), 289–297 (2005).
   Google Scholar
• Bertolaccini ML, Gomez S, Pareja JF et al. Antiphospholipid antibody tests: spreading the net. Ann. Rheum. Dis.64(11), 1639–1643 (2005).
   PubMed Web of Science ®Google Scholar